| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,390,000 |
| Market
Cap: |
422.36(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.15 - $24.1 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,568 |
159,192 |
218,988 |
| Total Sell Value |
$0 |
$137,243 |
$3,016,052 |
$4,045,075 |
| Total People Sold |
0 |
2 |
9 |
9 |
| Total Sell Transactions |
0 |
2 |
17 |
25 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Sushil |
Chief Strategy Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$281,129 |
D/D |
(15,575) |
154,571 |
|
13% |
|
| Lewis Tanya |
Chief Dev. Op. Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$220,336 |
D/D |
(12,207) |
148,153 |
|
13% |
|
| Love Colin |
Chief Operating Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$194,489 |
D/D |
(10,775) |
794,960 |
|
13% |
|
| Xynos Konstantinos |
Chief Medical Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$13,917 |
D/D |
(771) |
120,027 |
|
13% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2023-05-16 |
4 |
S |
$18.05 |
$107,686 |
D/D |
(5,966) |
263,436 |
|
13% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2022-12-09 |
4 |
AS |
$25.03 |
$375,450 |
D/D |
(15,000) |
229,402 |
|
-31% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2022-12-09 |
4 |
OE |
$1.01 |
$15,150 |
D/D |
15,000 |
244,402 |
|
- |
|
| Xynos Konstantinos |
Chief Medical OfficerOfficer |
• – – |
2022-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,298 |
|
-19% |
|
| Xynos Konstantinos |
Chief Medical Officer |
• – – |
2022-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
70,798 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2022-05-16 |
4 |
S |
$14.59 |
$51,167 |
D/D |
(3,507) |
229,402 |
|
-15% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2022-05-16 |
4 |
S |
$14.59 |
$50,131 |
D/D |
(3,436) |
95,099 |
|
-15% |
|
| Astley-Sparke Philip |
Chief Executive Officer |
• • – |
2022-05-16 |
4 |
S |
$14.59 |
$140,531 |
D/D |
(9,632) |
1,401,080 |
|
-15% |
|
| Coffin Robert |
President & Chief R&D Officer |
• • – |
2022-05-16 |
4 |
S |
$14.59 |
$83,703 |
D/D |
(5,737) |
1,796,197 |
|
-15% |
|
| Patel Sushil |
Chief Commercial Officer |
• – – |
2022-05-16 |
4 |
S |
$14.59 |
$155,923 |
D/D |
(10,687) |
130,146 |
|
-15% |
|
| Lewis Tanya |
Chief Dev. Op Officer |
• – – |
2022-05-16 |
4 |
S |
$14.59 |
$79,851 |
D/D |
(5,473) |
120,360 |
|
-15% |
|
| Love Colin |
Chief Operating Officer |
• – – |
2022-05-16 |
4 |
S |
$14.59 |
$92,267 |
D/D |
(6,324) |
765,735 |
|
-15% |
|
| Astley-Sparke Philip |
Chief Executive Officer |
• • – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
1,410,712 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,750 |
232,909 |
|
- |
|
| Love Colin |
Chief Operating Officer |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
772,059 |
|
- |
|
| Patel Sushil |
Chief Commercial Officer |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
140,833 |
|
- |
|
| Lewis Tanya |
Chief Dev.Op Off |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
125,833 |
|
- |
|
| Coffin Robert |
President & Chief R&D Officer |
• • – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
1,801,934 |
|
- |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
52,500 |
98,535 |
|
- |
|
| Stampacchia Otello |
10% Owner |
– – • |
2022-03-16 |
4 |
S |
$15.31 |
$698,253 |
D/D |
(45,000) |
4,673,380 |
|
-23% |
|
| Stampacchia Otello |
10% Owner |
– – • |
2022-03-15 |
4 |
S |
$15.64 |
$703,800 |
D/D |
(45,000) |
4,718,380 |
|
-21% |
|
172 Records found
|
|
Page 2 of 7 |
|
|
0.13 (1.85%) 
